ArticleMolecular biology reports2026
Theranekron attenuates lipopolysaccharide-induced neuroinflammation via NLRP3 inflammasome modulation.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dynamic effects of microglial NLRP3 on transcriptional alterations post-traumatic brain injury.Frontiers in neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAcute neuroinflammation plays a critical role in the pathogenesis of various central nervous system (CNS) disorders. Theranekron (TH), a homeopathic preparation derived from Tarantula cubensis venom, has demonstrated anti-inflammatory potential in several experimental models. This study aimed to evaluate the therapeutic efficacy of TH in a lipopolysaccharide (LPS) induced acute neuroinflammation model, focusing on oxidative stress parameters, histopathological changes, immunohistochemical markers, and key neuroinflammatory pathways involving the NOD-like receptor family, pyrin domain-containing protein 3 (NLRP3) inflammasome. METHODS AND
resultsThirty-two Wistar Albino rats were randomly divided into four groups: control, LPS (5 mg/kg, intraperitoneally), TH (0.2 ml, single dose, subcutaneously), and LPS + TH. Theranekron (0.2 mL, s.c.) was administered 30 min after LPS injection. Six hours after LPS administration, brain tissues were collected for the biochemical analyses of total antioxidant species (TAS), total oxidant species (TOS), and oxidative stress index (OSI)with histopathological and immunohistochemical analyses of tyrosine hydroxylase (TyrH) caspase-3 (Cas-3), tumor necrosis factor-alpha (TNF-α); and gene expression analyses of NLRP3, caspase 1 (Cas-1), interleukin-1 beta (IL-1β), and interleukin 18 (IL-18). LPS administration significantly increased Cas-3, TNF-α immunoexpression, TOS, OSI, and the expression of NLRP3, Cas-1, IL-1β, and IL-18 genes, while reducing TyrH immunoexpression and TAS levels. TH treatment reversed these alterations; demonstrating strong anti-inflammatory, antioxidant, and neuroprotective effects in the cerebral cortex, hippocampus and cerebellum.
conclusionsThis study provides compelling evidence that TH exerts potent neuroprotective effects by suppressing NLRP3 inflammasome activation, reducing oxidative stress, and restoring neurochemical homeostasis in an LPS-induced neuroinflammation model. These findings highlight TH as a promising therapeutic candidate for CNS inflammatory disorders, warranting further molecular and clinical investigation.
Indexed as
Identifiers
42189344What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.